SYF2

Across TCGA pan-cancer cohorts, SYF2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYF2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SYF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SYF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where SYF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.305	0.978	.006	35	view →
PDAC	DFS	Median	All	0.363	0.202	.013	17	view →
LUAD	OS	Tertile	III,IV	1.000	0.753	.007	13	view →
CCRCC	DFS	Median	II,III,IV	0.900	0.540	<.001	10	view →
LSCC	OS	Quartile	All	0.920	0.736	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYF2–HNSC (DFS)

Open the HNSC breakdown →